Hughes Steven George 4

4 · Atrium Therapeutics, Inc. · Filed Apr 22, 2026

AI-generated summary of this filing

Updated Apr 22, 2026

Atrium Therapeutics (RNA) CMO Steven G. Hughes Receives Stock Awards

What Happened

Steven G. Hughes, Chief Medical Officer of Atrium Therapeutics (RNA), received two awards reported on Form 4: 30,000 restricted stock units (RSUs) and 60,000 derivative awards, both recorded as acquired on 2026-04-20 at $0.00 (total cash paid = $0).
These are grants (insider code A), not open-market purchases or sales, so there was no immediate cash outlay or sale proceeds.

Key Details

Transaction date: 2026-04-20; Form 4 filed: 2026-04-22 (timely filing).
Grants: 30,000 RSUs @ $0.00 (F1) and 60,000 derivative awards @ $0.00 (F2); reported value $0 for each line.
Shares owned after transaction: not specified in the provided filing excerpt.
Footnotes:
- F1: The 30,000 RSUs each convert to one share. 25% vest on March 20, 2027, then the remainder vests in three substantially equal yearly installments thereafter, subject to continuous service.
- F2: For the 60,000 derivative award, 25% of the underlying shares vest on March 20, 2027, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to continuous service.
Filing timeliness: filed two days after the transaction (appears timely under Form 4 rules).

Context

These are grants/awards (not purchases or option exercises followed by sales). Awards typically vest over multiple years, so they represent future compensation rather than immediate insider buying or selling.
Derivative award (60,000) carries a staged vesting schedule; until vested, these do not confer immediate marketable shares.

Form 4

Period: 2026-04-20

Chief Medical Officer

Transactions

Award
Common Stock
[F1]
2026-04-20+30,000→ 73,097 total
Award
Stock Option (Right to Buy)
[F2]
2026-04-20+60,000→ 60,000 total
Exercise: $14.30Exp: 2036-04-20→ Common Stock (60,000 underlying)

Footnotes (2)

[F1]Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
[F2]Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Signature

/s/ Brendan Winslow, Attorney-in-Fact|2026-04-22

1 file